The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Albumin-based drug delivery: harnessing nature to cure disease
Open accessAbstract
The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein, F. H., Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,427
All About Albumin: Biochemistry, Genetics, and Medical Applications
Peters, T. (1995) · Thammasat University Digital Collections · Cited by 3,090
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
The Characterization of Two Specific Drug Binding Sites on Human Serum Albumin
SUDLOW, G., BIRKETT, D. J., & WADE, D. N. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10691-3 · Cited by 1,725
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Research works printed but not linked: 13
- Morris MA, Preddy L. Glycosylation accelerates albumin degradation in normal and diabetic dogs. Biochem Med Metab Biol. 1986;35(3):267–70. · doi:10.1016/0885-4505(86)90082-4
- Williams SK, Devenny JJ, Bitensky MW. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci U S A. 1981;78(4):2393–7. · doi:10.1073/pnas.78.4.2393
- Williams AM, Dickinson RG. Studies on the reactivity of acyl glucuronides--VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem Pharmacol. 1994;47(3):457–67. · doi:10.1016/0006-2952(94)90176-7
- Schnitzer J, Oh P. Antibodies to the albumin binding protein, albondin, inhibit transvascular transport of albumin in the rat lung. FASEB Journal. 1993;7(3–4):A902.
- Ottnad E, Via DP, Frubis J, Sinn H, Friedrich E, Ziegler R, et al. Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein. Biochem J. 1992;281(Pt 3):745–51. · doi:10.1042/bj2810745
- Storm T, Emma F, Verroust PJ, Hertz JM, Nielsen R, Christensen EI. A patient with cubilin deficiency. N Engl J Med. 2011;364(1):89–91. doi: 10.1056/NEJMc1009804 . · doi:10.1056/nejmc1009804
- Weyer K, Storm T, Shan J, Vainio S, Kozyraki R, Verroust PJ, et al. Mouse model of proximal tubule endocytic dysfunction. Nephrol Dial Transplant. 2011;26(11):3446–51. doi: 10.1093/ndt/gfr525 . · doi:10.1093/ndt/gfr525
- Malkinson M. The transmission of passive immunity to Escherichia coli from mother to young in the domestic fowl (Gallus domesticus). Immunology. 1965;9(4):311–7.
- Liberatore M, Clemente M, Iurilli AP, Zorzin L, Marini M, Di Rocco E, et al. Scintigraphic evaluation of disease activity in rheumatoid arthritis: a comparison of technetium-99 m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med. 1992;19(10):853–7. · doi:10.1007/bf00168160
- Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008;48(2):407–17. doi: 10.1002/hep.22403 . · doi:10.1002/hep.22403
- Colvin RA, Tanwandee T, Piratvisuth T, Thongsawat S, Hui AJ, Zhang H, et al. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2015;30(1):184–91. doi: 10.1111/jgh.12671 . · doi:10.1111/jgh.12671
- Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015;1(9):1271–80. doi: 10.1001/jamaoncol.2015.3101 . · doi:10.1001/jamaoncol.2015.3101
- Glaxo Smith Kline. http://www.gsk.com/en-gb/media/press-releases/2014/gsk-receives-us-approval-for-once-weekly-type-2-diabetes-treatment-tanzeum-albiglutide/ . Accessed Nov 13 2015.
Cited by
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Serum albumin in health and disease: esterase, antioxidant, transporting and signaling properties
Belinskaia, D. A., Voronina, P. A., Shmurak, V. I., Jenkins, R. O., & Goncharov, N. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910318 · Cited by 416
Hypoalbuminemia as Surrogate and Culprit of Infections
Wiedermann, C. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094496 · Cited by 394
Structural and biochemical features of human Serum albumin essential for eukaryotic cell culture
Mishra, V., & Heath, R. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168411 · Cited by 295
Rabbani, G., Baig, M. H., Lee, E. J., Cho, W.-K., Ma, J. Y., & Choi, I. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01124 · Cited by 287
Metadata
- Authors
- Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A.
- Venue
- Molecular and Cellular Therapies
- Publisher
- River Publishers
- Published
- 2016-02-27
- Volume
- 4
- Issue
- 1
- Pages
- 3-3
- ISSN
- 2052-8426 (ISSN-L)
- OpenAlex
- W2289794410
- Cited by
- 683
- References
- 115
- FWCI
- 26.33
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Styrelsen for Forskning og Innovation (102-2014-3)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albumin-based drug delivery: harnessing nature to cure disease. https://app.cochat.ai/papers/10.1186/s40591-016-0048-8
- The paper
- Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016). Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies. https://doi.org/10.1186/s40591-016-0048-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
